References
- Caldas IS, Talvani A, Caldas S, Carneiro CM, de Lana M, da Matta Guedes PM et al. Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesions. Parasitol Res 2008;103:413–421.
- Nogueira Silva JJ, Pavanelli WR, Gutierrez FR, Alves Lima FC, Ferreira da Silva AB, Santana Silva J et al. Complexation of the anti-Trypanosoma cruzi drug benznidazole improves solubility and efficacy. J Med Chem 2008;51:4104–4114.
- Santos DM, Martins TA, Caldas IS, Diniz LF, Machado-Coelho GL, Carneiro CM et al. Benznidazole alters the pattern of cyclophosphamide-induced reactivation in experimental Trypanosoma cruzi-dependent lineage infection. Acta Trop 2010;113:134–138.
- Lamas MC, Villaggi L, Nocito I, Bassani G, Leonardi D, Pascutti F et al. Development of parenteral formulations and evaluation of the biological activity of the trypanocide drug benznidazole. Int J Pharm 2006;307:239–243.
- Francisco AF, de Abreu Vieira PM, Arantes JM, Pedrosa ML, Martins HR, Silva M et al. Trypanosoma cruzi: Effect of benznidazole therapy combined with the iron chelator desferrioxamine in infected mice. Exp Parasitol 2008;120:314–319.
- Maximiano FP, Costa GHY, Souza JD, Cunha-Filho MSS. Physicalchemical characterization of antichagasic benznidazole. Quim Nova 2010;33:1714–1719.
- Leonardi D, Salomón CJ, Lamas MC, Olivieri AC. Development of novel formulations for Chagas’ disease: Optimization of benznidazole chitosan microparticles based on artificial neural networks. Int J Pharm 2009;367:140–147.
- Maximiano FP, de Paula LM, Figueiredo VP, de Andrade IM, Talvani A, Sá-Barreto LC et al. Benznidazole microcrystal preparation by solvent change precipitation and in vivo evaluation in the treatment of Chagas disease. Eur J Pharm Biopharm 2011;78:377–384.
- Maximiano FP, Costa GH, de Sá Barreto LC, Bahia MT, Cunha-Filho MS. Development of effervescent tablets containing benznidazole complexed with cyclodextrin. J Pharm Pharmacol 2011;63:786–793.
- Loftsson T, Duchêne D. Cyclodextrins and their pharmaceutical applications. Int J Pharm 2007;329:1–11.
- Lu Y, Tang Ning Qi, J, Wu Wei. Phase solubility behavior of hydrophilic polymer/cyclodextrin/lansoprazole ternary system studied at high polymer concentration and by response surface methodology. Pharm Dev Technol 2010; in print.
- USP 30. United States Pharmacopeia. 30th ed. United States Pharmacopeial Convention: Rockville; 2008.
- Vojnovic D, Chicco D. Mixture Experimental design applied to solubility predictions. Drug Dev Ind Pharm 1997;23:639–645.
- Carr RL. Evaluation of flow properties of solids. Chem Eng J 1965;72:163–168.
- Khan KA, Rhodes CT. Effect of compaction pressure on the dissolution efficiency of some direct compression systems. Pharm Acta Helv 1972;47:594–607.
- Szejtli J. Past present and future of cyclodextrin research. Pure Appl Chem 2004;76:1825–1845.
- Aleem O, Kuchekar B, Pore Y, Late S. Effect of β-cyclodextrin and hydroxypropyl β-cyclodextrin complexation on physicochemical properties and antimicrobial activity of cefdinir. J Pharm Biomed Anal 2008;47:535–540.
- Hedges AR. Industrial applications of cyclodextrins. Chem Rev 1998;98:2035–2044.
- Cunha-Filho MS, Dacunha-Marinho B, Torres-Labandeira JJ, Martínez-Pacheco R, Landín M. Characterization of β-lapachone and methylated β-cyclodextrin solid-state systems. AAPS PharmSciTech 2007;8:60.
- Fromming K, Szejtli J. Cyclodextrins in pharmacy. Dordrecht: Kluwer Academic Publishers; 1994.
- Basak SC, Reddy BMJ, Mani KPL. Formulation and release behaviour of sustained release ambroxol hydrochloride HPMC matrix tablet. Indian J Pharm Sci 2006;68:594–598.